RxDoctor Payments Data

Kyle Lehenbauer, MD

Cardiovascular Disease · Kansas City, MONPI 1871983577

Payments from drug & device makers

What this record shows

This record is dominated by grants: $98,000 of the $108,257 with a category attached, or 90.5%. Edwards Lifesciences accounts for 92.8% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $50,732 and has fallen 97.8% since, to $1,097 in 2025. Among cardiovascular disease clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$108,257in general payments, 2019–2025

Across 149 payments — averaging $726.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$100K
  • E.r. Squibb & Sons, L.L.C.$3K
  • Abbott$3K
  • Boston Scientific$1K
  • Medtronic$501
  • Novartis$356
  • plus $273 from 4 others

What the payments were for

  • Consulting fees$2,5602%
  • Grants$98,00091%
  • Travel & lodging$1,8182%
  • Food & beverage$5,8795%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$108,257 in reported general payments places this provider in the 95th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$124,026
Medicare patients
1,282
Services billed
1,964

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CamzyosMavacamten95$772,964
EliquisApixaban156$160,917
JardianceEmpagliflozin31$41,051
XareltoRivaroxaban17$24,451
OzempicSemaglutide13$12,345
FarxigaDapagliflozin Propanediol11$10,173
EntrestoSacubitril/Valsartan11$9,939
Metoprolol Succinate217$2,352
Atorvastatin Calcium135$1,133
Flecainide Acetate29$982
Diltiazem 24hr Er (Cd)Diltiazem Hcl47$851
Nebivolol Hcl12$765
Ezetimibe39$732
Rosuvastatin Calcium68$693
Losartan Potassium76$670

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$2,916$772,96495 claims
Boehringer IngelheimJardiance$49$41,05131 claims
NovartisEntresto$356$9,93911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →